Mirage IV

Indication :

Mirage is indicated for the treatment of the following infections in adults and children over 3 months of age: severe pneumonia, including hospital and ventilator-associated, pneumonia, broncho-pulmonary infections in cystic fibrosis, complicated urinary tract infections, complicated intra-abdominal infections, intra- and post-partum infections, complicated skin and soft tissue infections , acute bacterial meningitis, Mirage may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Treatment of patients with bacteraemia that occurs in association with/or is suspected to be associated with any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Composition :

For Mirage 1 gm; each vial contains:

Active Ingredient

Meropenem 1 gm

Inactive Ingredient:

Sodium carbonate 207.8 mg (Equivalent to 90.2 mg elemental sodium)

For Mirage 0.5 gm; each vial contains:

Active Ingredient

Meropenem 500 mg

Inactive Ingredient:

Sodium carbonate 104 mg (Equivalent to 45.1 mg elemental sodium)